《中国期刊全文数据库》收录期刊
《中国核心期刊(遴选)数据库》收录期刊
《中文科技期刊数据库》收录期刊

Surgical Research and New Technique ›› 2021, Vol. 10 ›› Issue (3): 182-185.doi: 10.3969/j.issn.2095-378X.2021.03.007

• Original article • Previous Articles     Next Articles

Clinical effect of intraperitoneal hyperthermic perfusion with oxaliplatin on ovarian cancer and its survival

CAI Xiaohua, MO Jinsi, RONG Xiumei   

  1. Department of Gynecology, Yangjiang People’s Hospital, Yangjiang 529500, Guangdong, China
  • Received:2021-01-12 Online:2021-09-28 Published:2022-08-22

Abstract: Objective To investigate the clinical effect of intraperitoneal hyperthermic perfusion with oxaliplatin on ovarian cancer. Methods A total of 68 patients with advanced ovarian cancer treated in our hospital from January 2017 to January 2019 were divided into an observation group (n=35) and a control group (n=33) according to treatment plans. Both the groups were given docetaxel through intravenous drip. The observation group was additionally given oxaliplatin intraperitoneal thermal perfusion, while the control group was additionally given oxaliplatin intravenous drip. The treatment effects, adverse reactions, and progression-free survival of the two groups were observed. Results The total curative effective rate of chemotherapy in the observation group was 74.29%, higher than that in the control group (P<0.05). The ascites volume of the observation group after treatment was (760.35±110.21) mL, which was significantly lower than that of the control group (P<0.05). The levels of serum carbohydrate antigen 125 (CA125) and squamous cell carcinoma antigen (SCCA) in the observation group were (12.21±2.15) U/mL and (8.28±1.82) ng/mL, respectively, which were significantly lower than those in the control group (P<0.05). The progression-free survival of the observation group was 15 (95%CI: 13.21-16.79) months, which was significantly longer than that of the control group (P<0.05). There was no significant difference in adverse reactions between the observation group and the control group (P>0.05). Conclusion Oxaliplatin intraperitoneal hyperthermic perfusion has a good clinical effect on ovarian cancer and prolongs survival.

Key words: Oxaliplatin, Intraperitoneal hyperthermic perfusion, Ovarian cancer, Clinical effect, Survival

CLC Number: